Dr. Reddy’s Biosimilar Products
Dr. Reddy's Biologics is committed to providing affordable and innovative Biosimilars that are within reach. Over and above the six biosimilars launched in the market, Biologics has a growing portfolio of molecules primarily in the space of Oncology & auto-immune disorders. Every step we take is rooted in our unwavering commitment to improving lives globally.
Biosimilars
A biologic, or biopharmaceutical, is a medicinal product derived from living organisms (plants, animals, or microorganisms), often created using recombinant DNA technology. A biosimilar is a biologic that closely resembles an already authorised reference biologic, with no significant differences in quality, safety, or efficacy. Our biosimilar products are developed with the Totality of Evidence approach, as defined by FDA, WHO, and other regulatory bodies.
Our Products
7 Commercially Approved Products .
Our Pipeline
Within the areas of oncology, auto-immune disorders, osteoporosis and ALS, Dr. Reddy’s Biologics team is working on developing over ten products, including novel molecules. The future is coming, and it is hopeful.
- *In-licensed
Product
Therapeutic Area
Type
Early Development
Pre Clinical
Phase1
Phase3
Under Approval
Denosumab*
Oncology, Osteoporosis
Monoclonal Antibody
Abatacept
Auto- immune, Rheumatoid arthritis
Fc Fusion Protein
Daratumumab*
Oncology
Monoclonal Antibody
We Meet Global Standards
Our Expertise in Biologics
Dr. Reddy's Biologics is dedicated to making advanced medicines accessible worldwide. Our experienced team, coupled with world-class infrastructure, enables us to create effective biosimilars that reduce the cost burden on patients and payers. As a leader in the fast-growing biosimilar sector, Dr.Reddy's Biologics markets six biosimilars across multiple countries and has a robust pipeline in development.
- Publication
- 23-04-2025
Abstract No: 0556, ISNCON Conference 2014 Efficacy and Safety of Indigenously Developed Darbepoetin Alfa in Dialysis Patients - A Randomised Study
- News
- 07-06-2025
Alvotech and Dr. Reddy’s to co-develop biosimilar candidate to Keytruda® (pembrolizumab)
- Publication
- 12-02-2020
Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus ReferenceRituximab in Biologics‑Naïve Patients with Moderate‑to‑SevereRheumatoid Arthritis: A Double‑Blind, Randomized, Three‑Arm Study
- Publication
- 06-12-2019
Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma
Meena Iyer
Quality
Palak Shukla
Product Dev.
Babula Mohanty
Packaging
Shyamalini S
Clinical Dev.
Hemanth Bhargav
Quality
Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.
Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.